Tag: BioAge Labs

RICHMOND, Calif. [Dec. 5, 2022] — BioAge Labs, Inc. (“BioAge”), a clinical-stage biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today announced positive results for an important new study. The study used Phase 1b clinical data for BGE-105, for a highly selective, potent, orally available small-molecule agonist…